Results of a phase 2 study of a novel DLL4-VEGF, a bispecific antibody, tovecimig (CTX-009), as a monotherapy in patients with refractory metastatic colorectal cancer (COMPANION-003). Nivolumab plus ...
Performing SLNB or cALND solely to determine eligibility for CDK4/6 inhibition requires very high number needed to diagnose and treat, adds substantial morbidity, and is costly, with only marginal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results